Bangladesh DGHS 2026: kala-azar and other leishmaniasis
Bangladesh national DGHS Bangladesh Current
National Guideline for Management of Kala-azar (clinical management)
National Kala-azar Elimination Programme, CDC, DGHS, Bangladesh. 2026
Summary checked against the source: 2026-11
Distributed by the National Kala-azar Elimination Programme, DGHS; see the local PDF Kala-azar_DGHS_2026_Guideline.pdf
National Kala-azar Elimination Programme (NKEP) clinical management guideline. Bangladesh was the first country certified for eliminating kala-azar as a public health problem (October 2023); the aim now is to stop transmission. Page numbers are the guideline's printed pages.
At a glance
- Primary kala-azar (PKA): fever >2 weeks + lives in or visited an endemic area + splenomegaly + positive rK39 RDT (or molecular test). [p. 17]
- First line changed: from single-dose to multiple-dose liposomal amphotericin B: 15 mg/kg as 5 mg/kg on days 1, 3 and 5, because single dose led to more PKDL and relapse. [Table 12 · p. 30]
- Relapse or treatment failure: LAmB 15 mg/kg + miltefosine for 7 days, after parasitological confirmation. [Table 14 · p. 32]
- PKDL treatment depends on grade: macular lesions get miltefosine for 12 weeks (or LAmB). [Table 18 · p. 35]
- Miltefosine is teratogenic: contraception during and for 5 months after; never in pregnancy or without contraception. [Table 9 · p. 28]
- Final cure is assessed 6 months after treatment. [Table 13 · p. 31]
Case definitions
| Entity | Definition |
|---|---|
| Primary kala-azar (PKA) (formerly "new KA") | Fever >2 weeks, AND living in or travel to an endemic area, AND splenomegaly, AND rK39 RDT and/or molecular test positive. Supporting: weight loss, anaemia, darkening of the skin, hepatomegaly |
| Treatment failure (KATF) | Treated PKA, no improvement within 15 days, or symptoms return within 6 months of the end of treatment; plus parasites demonstrated |
| Relapse (RKA) | Treated PKA, symptoms return after 6 months; plus parasites demonstrated |
| Refractory (RfKA) | Two previous relapses treated with standard regimens, then another relapse after 6 months; plus parasites demonstrated |
| PKDL | Previous kala-azar and/or living in an endemic area, AND hypopigmented macules, papules or nodules with intact sensation, excluding leprosy, vitiligo, pityriasis, tinea, arsenicosis. rK39 positive = probable; LD bodies on slit-skin smear or biopsy = confirmed |
| Relapse PKDL | Declared cured at 12 months, then new lesions after 24 months; rK39 or parasite confirmation |
Adapted from BD-DGHS 2026 sections 2.2–2.3 [p. 17–19]
Parasitological confirmation is mandatory for KATF, RKA, RfKA, relapse PKDL, para-KDL and cutaneous leishmaniasis, and for suspected kala-azar with a negative rK39, previous kala-azar or HIV: LD bodies or PCR from splenic aspirate (most sensitive), bone marrow, skin or buffy coat. [p. 16–17]
Diagnosis
- rK39 RDT: highly sensitive and specific screening test, used at upazila level. Stays positive after treatment, so it's not useful for relapse. [p. 16]
- PCR: 85–100% sensitive, 100% specific. [p. 16]
- PKDL: the macular form is commonest in Bangladesh, often atypical in distribution. rK39 is usually positive in papular and nodular lesions; a negative test doesn't exclude macular PKDL. Develops in 3–25% after kala-azar; 10% have no previous kala-azar. [p. 19–20]
| PKDL | Leprosy | |
|---|---|---|
| Age | Young | Older |
| Lesions | Symmetrical, uniform, sun-exposed areas | Often single or asymmetrical (tuberculoid) |
| Sensation, nerves | Normal sensation, no thickened nerves | Anaesthetic patches, thickened nerves, loss of sweating |
| Smear | LD bodies (Giemsa) | Acid-fast bacilli (modified ZN) |
Adapted from BD-DGHS 2026 Table 4 [p. 20]
Treatment of primary kala-azar
Before treatment: FBC, SGPT, creatinine, electrolytes, albumin (PT if aspiration planned). Pregnancy test before miltefosine. For KATF, RKA and RfKA add HIV, glucose, HbA1c, Mantoux, CXR and GeneXpert where relevant. [Tables 10–11 · p. 29]
Supportive care: nutrition; transfuse to Hb ≥7 g/dL; treat intercurrent infections (the main cause of death), with prophylactic antibiotics for neutrophils <1500/mm³ on specialist advice; oral and skin hygiene (cancrum oris). [p. 29]
| Line | Regimen |
|---|---|
| First choice | Liposomal amphotericin B (LAmB) 15 mg/kg total: 5 mg/kg on days 1, 3 and 5 |
| Alternatives (by availability) | 1. LAmB 5 mg/kg single dose + miltefosine 7 days 2. LAmB 5 mg/kg single dose + paromomycin 15 mg/kg/day IM for 10 days 3. Paromomycin 15 mg/kg/day IM + miltefosine, both for 10 days |
| Second line | Amphotericin B deoxycholate 0.75–1 mg/kg daily or alternate days for 15–20 days; or sodium stibogluconate 20 mg Sb⁵⁺/kg/day IM for 30 days |
Adapted from BD-DGHS 2026 Table 12 [p. 30]
Miltefosine dose: 2.5 mg/kg twice daily (max 150 mg/day), or by age and weight: 2–11 years 2.5 mg/kg twice daily (≤50 mg/day); ≥12 years <25 kg 50 mg daily; 25–50 kg 50 mg twice daily; adults >50 kg 75 mg twice daily, with food. Missed >7 days: restart. [p. 31]
| Cure | When | Criteria |
|---|---|---|
| Initial | 15 days after treatment | No fever, smaller spleen, weight gain |
| Final | 6 months after treatment | No fever, spleen much smaller or impalpable, well, weight gain (plus negative aspirate or PCR after KATF or RKA) |
Adapted from BD-DGHS 2026 Tables 13 and 15 [p. 31, 33]
Relapse, failure and refractory disease
| Case | Regimen |
|---|---|
| KATF or RKA, first line | LAmB 15 mg/kg (3 alternate-day doses) + miltefosine 7 days |
| KATF or RKA, second line | LAmB 15 mg/kg + paromomycin 10 days; or paromomycin + miltefosine |
| Refractory (RfKA) | Loading: LAmB 15 mg/kg + miltefosine 7 days, then secondary prophylaxis LAmB 7.5 mg/kg monthly for 5 months, at a tertiary centre under an ID specialist; check CD4 and immunoglobulins |
Adapted from BD-DGHS 2026 Tables 14 and 16 [p. 32–33]
Risk factors for relapse: HIV, pedal oedema, low platelets on admission, secondary pneumonia. [p. 32]
PKDL
| Grade | First line |
|---|---|
| 1: macular lesions only | Miltefosine for 12 weeks, or LAmB 15 mg/kg in 3 doses |
| 2: mixed maculopapular and nodular | LAmB 15 mg/kg (2–3 doses) + miltefosine 28 days |
| 3: dense lesions over most of the body | LAmB extended dose: two monthly cycles of 20 mg/kg (4 × 5 mg/kg) |
| Relapse PKDL | LAmB 15 mg/kg + miltefosine 28 days, under an ID specialist |
Grades 2 and 3 are referred to tertiary centres. Lesions take a further 4–6 months to clear after treatment. Adapted from BD-DGHS 2026 Tables 18–19 [p. 35–36]
Risk factors for PKDL: inadequate kala-azar treatment, younger age, HIV or ART, malnutrition, persistent parasites. [p. 34]
Drugs and cautions
| Drug | Key cautions |
|---|---|
| Liposomal amphotericin B | Test dose (hypersensitivity); monitor creatinine and electrolytes |
| Miltefosine (oral) | Teratogenic: pregnancy test; contraindicated in married women of reproductive age not using contraception; contraception during and 5 months after; eye check (vision, colour vision); may cause infertility; liver and renal monitoring |
| Paromomycin (IM) | Liver, renal and vestibular monitoring |
| Amphotericin B deoxycholate | Renal monitoring |
| Sodium stibogluconate | Phlebitis, cardiac monitoring, pancreatitis |
Adapted from BD-DGHS 2026 Table 9 [p. 28]
Special situations (treat in specialised centres): HIV, TB, diabetes, pregnancy, breastfeeding, women of reproductive age without contraception, asthma, chronic liver or kidney disease, severe anaemia (Hb <7 g/dL). With HIV, allow about 2 weeks between kala-azar treatment and ART if CD4 is very low (IRIS). [p. 50–51]
Clinical pearls
- Fever >2 weeks + splenomegaly + endemic area + rK39 positive = kala-azar.
- LAmB 5 mg/kg on days 1, 3, 5 (15 mg/kg) is now first line in Bangladesh.
- Relapse = after 6 months; failure = within 6 months or no response by 15 days. Both need parasite confirmation.
- PKDL: hypopigmented macules with normal sensation; miltefosine 12 weeks.
- Miltefosine: teratogenic, contraception for 5 months after.
Classes and levels of evidence
DGHS 2026 is a national programme guideline. It gives standard regimens and operational instructions without grading them by class or level of evidence, so citations on this page give only the page number in the original document. Where it follows WHO guidance, the strength of the WHO recommendation isn't restated.